2C7S

Crystal structure of human protein tyrosine phosphatase kappa at 1.95A resolution

2C7S の概要

• エントリーDOI: 10.2210/pdb2c7s/pdb
• 分子名称: RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE KAPPA, ACETATE ION (3 entities in total)
• 機能のキーワード: receptor type tyrosine phosphatase kappa, ptprk, glycoprotein, hydrolase, immunoglobulin domain, protein phosphatase, receptor, transmembrane
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 36124.74

構造登録者

Debreczeni, J.E.,Ugochukwu, E.,Eswaran, J.,Barr, A.,Das, S.,Burgess, N.,Gileadi, O.,Longman, E.,von Delft, F.,Knapp, S.,Sundstron, M.,Arrowsmith, C.,Weigelt, J.,Edwards, A. (登録日: 2005-11-28, 公開日: 2007-01-02, 最終更新日: 2024-11-13)

主引用文献

Eswaran, J.,Debreczeni, J.E.,Longman, E.,Barr, A.J.,Knapp, S.
The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1.
Protein Sci., 15:1500-1505, 2006

PubMed Abstract: The receptor-type protein tyrosine phosphatases (RPTPs) are integral membrane proteins composed of extracellular adhesion molecule-like domains, a single transmembrane domain, and a cytoplasmic domain. The cytoplasmic domain consists of tandem PTP domains, of which the D1 domain is enzymatically active. RPTPkappa is a member of the R2A/IIb subfamily of RPTPs along with RPTPmu, RPTPrho, and RPTPlambda. Here, we have determined the crystal structure of catalytically active, monomeric D1 domain of RPTPkappa at 1.9 A. Structural comparison with other PTP family members indicates an overall classical PTP architecture of twisted mixed beta-sheets flanked by alpha-helices, in which the catalytically important WPD loop is in an unhindered open conformation. Though the residues forming the dimeric interface in the RPTPmu structure are all conserved, they are not involved in the protein-protein interaction in RPTPkappa. The N-terminal beta-strand, formed by betax association with betay, is conserved only in RPTPs but not in cytosolic PTPs, and this feature is conserved in the RPTPkappa structure forming a beta-strand. Analytical ultracentrifugation studies show that the presence of reducing agents and higher ionic strength are necessary to maintain RPTPkappa as a monomer. In this family the crystal structure of catalytically active RPTPmu D1 was solved as a dimer, but the dimerization was proposed to be a consequence of crystallization since the protein was monomeric in solution. In agreement, we show that RPTPkappa is monomeric in solution and crystal structure.

PubMed: 16672235
DOI: 10.1110/ps.062128706

実験手法

X-RAY DIFFRACTION (1.95 Å)